Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282919200> ?p ?o ?g. }
- W4282919200 endingPage "739" @default.
- W4282919200 startingPage "726" @default.
- W4282919200 abstract "Extensive exposure to prescription-type opioids has resulted in major harm worldwide, calling for better-adapted approaches to opioid agonist therapy. The authors aimed to determine whether flexible take-home buprenorphine/naloxone is as effective as supervised methadone in reducing opioid use in prescription-type opioid consumers with opioid use disorder.This seven-site, pan-Canadian, 24-week, pragmatic, open-label, noninferiority, two-arm parallel randomized controlled trial involved treatment-seeking adults with prescription-type opioid use disorder. Participants were randomized in a 1:1 ratio to treatment with sublingual buprenorphine/naloxone (target dosage, 8 mg/2 mg to 24 mg/6 mg per day; flexible take-home dosing) or oral methadone (≈60-120 mg/day; closely supervised). The primary outcome was the proportion of opioid-free urine drug screens over 24 weeks (noninferiority margin, 15%). All randomized participants were analyzed, excluding one who died shortly after randomization, for the primary analysis (modified intention-to-treat analysis).Of 272 participants recruited (mean age, 39 years [SD=11]; 34.2% female), 138 were randomized to buprenorphine/naloxone and 134 to methadone. The mean proportion of opioid-free urine drug screens was 24.0% (SD=34.4) in the buprenorphine/naloxone group and 18.5% (SD=30.5) in the methadone group, with a 5.6% adjusted mean difference (95% CI=-0.3, +∞). Participants in the buprenorphine/naloxone group had 0.47 times the odds (95% CI=0.24, 0.90) of being retained in the assigned treatment compared with those in the methadone group. Overall, 24 drug-related adverse events were reported (12 in the buprenorphine/naloxone group [N=8/138; 5.7%] and 12 in the methadone group [N=12/134; 9.0%]) and mostly included withdrawal, hypogonadism, and overdose.The buprenorphine/naloxone flexible model of care was safe and noninferior to methadone in reducing opioid use among people with prescription-type opioid use disorder. This flexibility could help expand access to opioid agonist therapy and reduce harms in the context of the opioid overdose crisis." @default.
- W4282919200 created "2022-06-16" @default.
- W4282919200 creator A5021664754 @default.
- W4282919200 creator A5022217018 @default.
- W4282919200 creator A5026999658 @default.
- W4282919200 creator A5031049285 @default.
- W4282919200 creator A5037775461 @default.
- W4282919200 creator A5041290896 @default.
- W4282919200 creator A5052787286 @default.
- W4282919200 creator A5061043962 @default.
- W4282919200 creator A5061218451 @default.
- W4282919200 creator A5061560140 @default.
- W4282919200 creator A5067734183 @default.
- W4282919200 creator A5070915003 @default.
- W4282919200 creator A5074084071 @default.
- W4282919200 creator A5075658756 @default.
- W4282919200 creator A5080697414 @default.
- W4282919200 creator A9999999999 @default.
- W4282919200 date "2022-10-01" @default.
- W4282919200 modified "2023-10-17" @default.
- W4282919200 title "Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial" @default.
- W4282919200 cites W125827253 @default.
- W4282919200 cites W1906991930 @default.
- W4282919200 cites W1967114531 @default.
- W4282919200 cites W1968420582 @default.
- W4282919200 cites W1973849525 @default.
- W4282919200 cites W1979184030 @default.
- W4282919200 cites W1996055083 @default.
- W4282919200 cites W2007802571 @default.
- W4282919200 cites W2014690451 @default.
- W4282919200 cites W2026634677 @default.
- W4282919200 cites W2052551617 @default.
- W4282919200 cites W2097398776 @default.
- W4282919200 cites W2112174894 @default.
- W4282919200 cites W2126701437 @default.
- W4282919200 cites W2135214206 @default.
- W4282919200 cites W2148488822 @default.
- W4282919200 cites W2151383246 @default.
- W4282919200 cites W2151493975 @default.
- W4282919200 cites W2592870800 @default.
- W4282919200 cites W2725503094 @default.
- W4282919200 cites W2739913519 @default.
- W4282919200 cites W2791607419 @default.
- W4282919200 cites W2795456703 @default.
- W4282919200 cites W2805509675 @default.
- W4282919200 cites W2884069261 @default.
- W4282919200 cites W2914014906 @default.
- W4282919200 cites W2967315114 @default.
- W4282919200 cites W2982015067 @default.
- W4282919200 cites W2993287958 @default.
- W4282919200 cites W3094506985 @default.
- W4282919200 cites W3159652031 @default.
- W4282919200 cites W3170670183 @default.
- W4282919200 doi "https://doi.org/10.1176/appi.ajp.21090964" @default.
- W4282919200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35702828" @default.
- W4282919200 hasPublicationYear "2022" @default.
- W4282919200 type Work @default.
- W4282919200 citedByCount "20" @default.
- W4282919200 countsByYear W42829192002022 @default.
- W4282919200 countsByYear W42829192002023 @default.
- W4282919200 crossrefType "journal-article" @default.
- W4282919200 hasAuthorship W4282919200A5021664754 @default.
- W4282919200 hasAuthorship W4282919200A5022217018 @default.
- W4282919200 hasAuthorship W4282919200A5026999658 @default.
- W4282919200 hasAuthorship W4282919200A5031049285 @default.
- W4282919200 hasAuthorship W4282919200A5037775461 @default.
- W4282919200 hasAuthorship W4282919200A5041290896 @default.
- W4282919200 hasAuthorship W4282919200A5052787286 @default.
- W4282919200 hasAuthorship W4282919200A5061043962 @default.
- W4282919200 hasAuthorship W4282919200A5061218451 @default.
- W4282919200 hasAuthorship W4282919200A5061560140 @default.
- W4282919200 hasAuthorship W4282919200A5067734183 @default.
- W4282919200 hasAuthorship W4282919200A5070915003 @default.
- W4282919200 hasAuthorship W4282919200A5074084071 @default.
- W4282919200 hasAuthorship W4282919200A5075658756 @default.
- W4282919200 hasAuthorship W4282919200A5080697414 @default.
- W4282919200 hasAuthorship W4282919200A9999999999 @default.
- W4282919200 hasConcept C126322002 @default.
- W4282919200 hasConcept C168563851 @default.
- W4282919200 hasConcept C170493617 @default.
- W4282919200 hasConcept C204243189 @default.
- W4282919200 hasConcept C2778750930 @default.
- W4282919200 hasConcept C2778767360 @default.
- W4282919200 hasConcept C2778949969 @default.
- W4282919200 hasConcept C2779418921 @default.
- W4282919200 hasConcept C2781063702 @default.
- W4282919200 hasConcept C42219234 @default.
- W4282919200 hasConcept C71924100 @default.
- W4282919200 hasConceptScore W4282919200C126322002 @default.
- W4282919200 hasConceptScore W4282919200C168563851 @default.
- W4282919200 hasConceptScore W4282919200C170493617 @default.
- W4282919200 hasConceptScore W4282919200C204243189 @default.
- W4282919200 hasConceptScore W4282919200C2778750930 @default.
- W4282919200 hasConceptScore W4282919200C2778767360 @default.
- W4282919200 hasConceptScore W4282919200C2778949969 @default.
- W4282919200 hasConceptScore W4282919200C2779418921 @default.
- W4282919200 hasConceptScore W4282919200C2781063702 @default.
- W4282919200 hasConceptScore W4282919200C42219234 @default.